Natural killer activity and antibody-dependent cellular cytotoxicity in patients with primary lung cancer. 1992

S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea.

The NK activity and ADCC of peripheral blood mononuclear cell were examined to evaluate the contribution of ADCC and NK activity to host immune response against lung cancer. The NK activity and ADCC were examined in 58 patients with primary lung cancer and 40 healthy volunteers as normal controls. The NK activity of patients with lung cancer was significantly subnormal, but ADCC was at a normal level. The NK activity was decreased in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC) compared to normal controls. According to stage, the NK activity in stage II, III-M0 and III-M1 NSCLC showed low levels compared to that of stage I NSCLC, but there was no difference of NK activity in patients with SCLC. The NK activity was not affected by performance status. There was no significant difference of ADCC in patients with lung cancer according to cell type, stage and performance compared with that of normal controls. The NK activity and ADCC were not changed after chemotherapy and operation respectively.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell

Related Publications

S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
January 1988, Neoplasma,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
January 1982, Journal of cancer research and clinical oncology,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
July 1989, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
January 1984, Leukemia research,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
January 1986, Cancer immunology, immunotherapy : CII,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
May 1982, Acta paediatrica Scandinavica,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
June 1990, Clinical and experimental immunology,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
July 1987, Clinical immunology and immunopathology,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
February 1990, Acta paediatrica Japonica : Overseas edition,
S K Kim, and C H Cho, and C M Ahn, and S H Jang, and Y H Lee, and S K Kim, and J Chang, and B K Lee, and S J Kim, and J K Youn
January 1987, Clinical nephrology,
Copied contents to your clipboard!